Genes associated with metabolic syndrome predict disease-free survival in stage II colorectal cancer patients. A novel link between metabolic dysregulation and colorectal cancer

Molecular Oncology

Volumn 8, Issue 8, 2014, Pages 1469-1481

  Vargas, Teodoro ^a   Moreno Rubio, Juan ^b,c   Herranz, Jesús ^a   Cejas, Paloma ^b   Molina, Susana ^a   González Vallinas, Margarita ^a   Ramos, Ricardo ^d   Burgos, Emilio ^b   Aguayo, Cristina ^b   Custodio, Ana B ^b   Reglero, Guillermo ^a,e   Feliu, Jaime ^b   Ramírez de Molina, Ana ^a  

^a IMDEA FOOD INSTITUTE   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^c HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^d Genomics Laboratory   (Spain)

^e INSTITUTE OF FOOD SCIENCE RESEARCH CIAL   (Spain)

Author keywords

Apolipoproteins; Colorectal cancer; Metabolic syndrome; Prognostic biomarker

Indexed keywords

ABC TRANSPORTER A1; ANTINEOPLASTIC AGENT; APOLIPOPROTEIN A2; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN D; LEPTIN RECEPTOR;

ABC TRANSPORTER A1 GENE; ADULT; AGED; APOLIPOPROTEIN A2 GENE; APOLIPOPROTEIN C1 GENE; APOLIPOPROTEIN C2 GENE; APOLIPOPROTEIN D GENE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC RISK; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; LEPTIN RECEPTOR GENE; LIPID TRANSPORT; LOW RISK PATIENT; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PERINEURAL INVASION; PREDICTION; PREDICTIVE VALUE; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME;

EID: 84907680203     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.05.015     Document Type: Article

References (56)

1. Agesen T.H., Sveen A., Merok M.A., Lind G.E., Nesbakken A., Skotheim R.I., Lothe R.A. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut 2012, 61:1560-1567.
2. AHA,. American Heart Association. http://www.heart.org/HEARTORG/.
3. Aleksandrova K., Boeing H., Jenab M., Bas Bueno-de-Mesquita H., Jansen E., van Duijnhoven F.J., Fedirko V., Rinaldi S., Romieu I., Riboli E., Romaguera D., Overvad K., Ostergaard J.N., Olsen A., Tjonneland A., Boutron-Ruault M.C., Clavel-Chapelon F., Morois S., Masala G., Agnoli C., Panico S., Tumino R., Vineis P., Kaaks R., Lukanova A., Trichopoulou A., Naska A., Bamia C., Peeters P.H., Rodriguez L., Buckland G., Sanchez M.J., Dorronsoro M., Huerta J.M., Barricarte A., Hallmans G., Palmqvist R., Khaw K.T., Wareham N., Allen N.E., Tsilidis K.K., Pischon T. Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study. Cancer Prev. Res. 2011, 4:1873-1883.
4. Alvarez M.L., Barbon J.J., Gonzalez L.O., Abelairas J., Boto A., Vizoso F. Apolipoprotein D expression in retinoblastoma. Ophthalmic Res. 2003, 35:111-116.
5. Avery C.L., He Q., North K.E., Ambite J.L., Boerwinkle E., Fornage M., Hindorff L.A., Kooperberg C., Meigs J.B., Pankow J.S., Pendergrass S.A., Psaty B.M., Ritchie M.D., Rotter J.I., Taylor K.D., Wilkens L.R., Heiss G., Lin D.Y. A phenomics-based strategy identifies loci on APOC1, BRAP, and PLCG1 associated with metabolic syndrome phenotype domains. PLoS Genet. 2011, 7:e1002322.
6. Bardou M., Barkun A.N., Martel M. Obesity and colorectal cancer. Gut 2013, 62:933-947.
7. Beccari S., Kovalszky I., Wade J.D., Otvos L., Surmacz E. Designer peptide antagonist of the leptin receptor with peripheral antineoplastic activity. Peptides 2013, 44:127-134.
8. Claerhout S., Lim J.Y., Choi W., Park Y.Y., Kim K., Kim S.B., Lee J.S., Mills G.B., Cho J.Y. Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. PloS One 2011, 6:e24662.
9. Corella D., Tai E.S., Sorli J.V., Chew S.K., Coltell O., Sotos-Prieto M., Garcia-Rios A., Estruch R., Ordovas J.M. Association between the APOA2 promoter polymorphism and body weight in Mediterranean and Asian populations: replication of a gene-saturated fat interaction. Int. J. Obesity 2011, 35:666-675.
10. Chung Y.C., Chaen Y.L., Hsu C.P. Clinical significance of tissue expression of interleukin-6 in colorectal carcinoma. Anticancer Res. 2006, 26:3905-3911.
11. Dowling R.J., Goodwin P.J., Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Medicine 2011, 9:33.
12. Eschrich S., Yang I., Bloom G., Kwong K.Y., Boulware D., Cantor A., Coppola D., Kruhoffer M., Aaltonen L., Orntoft T.F., Quackenbush J., Yeatman T.J. Molecular staging for survival prediction of colorectal cancer patients. J.Clinical Oncol. Offic. J. Am. Soc. Clin. Oncol. 2005, 23:3526-3535.
13. Esposito K., Chiodini P., Capuano A., Bellastella G., Maiorino M.I., Rafaniello C., Panagiotakos D.B., Giugliano D. Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine 2013, 44:634-647.
14. Garrett C.R., Hassabo H.M., Bhadkamkar N.A., Wen S., Baladandayuthapani V., Kee B.K., Eng C., Hassan M.M. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br. J. Cancer 2012, 106:1374-1378.
15. Gonzalez R.R., Cherfils S., Escobar M., Yoo J.H., Carino C., Styer A.K., Sullivan B.T., Sakamoto H., Olawaiye A., Serikawa T., Lynch M.P., Rueda B.R. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J.Biol. Chem. 2006, 281:26320-26328.
16. Gray R.G., Quirke P., Handley K., Lopatin M., Magill L., Baehner F.L., Beaumont C., Clark-Langone K.M., Yoshizawa C.N., Lee M., Watson D., Shak S., Kerr D.J. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J.Clinical Oncol. Official J. Am. Soc. Clin. Oncol. 2011, 29:4611-4619.
17. Guadagni F., Roselli M., Martini F., Spila A., Riondino S., D'Alessandro R., Del Monte G., Formica V., Laudisi A., Portarena I., Palmirotta R., Ferroni P. Prognostic significance of serum adipokine levels in colorectal cancer patients. Anticancer Res. 2009, 29:3321-3327.
18. Harrell F.E., Lee K.L., Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 1996, 15:361-387.
19. Hull M., Lagergren J. Obesity and colorectal cancer. Gut 2013, 63:205.
20. Ishino K., Mutoh M., Totsuka Y., Nakagama H. Metabolic syndrome: a novel high-risk state for colorectal cancer. Cancer Lett 2012, S0304-3835(12)00600-3. http://dx.doi.org/10.1016/j.canlet.2012.10.012.
21. Kankesan J., Laconi E., Medline A., Thiessen J.J., Ling V., Rao P.M., Rajalakshmi S., Sarma D.S. PSC 833, an inhibitor of P-glycoprotein inhibits 1,2-dimethylhydrazine-induced colorectal carcinogenesis in male Fischer F344 rats. Anticancer Res. 2006, 26:995-999.
22. Kim B.C., Shin A., Hong C.W., Sohn D.K., Han K.S., Ryu K.H., Park B.J., Nam J.H., Park J.W., Chang H.J., Choi H.S., Kim J., Oh J.H. Association of colorectal adenoma with components of metabolic syndrome. Canc. Caus. Cont. 2012, 23:727-735.
23. Kim J.H., Lim Y.J., Kim Y.H., Sung I.K., Shim S.G., Oh S.O., Park S.S., Yang S., Son H.J., Rhee P.L., Kim J.J., Rhee J.C., Choi Y.H. Is metabolic syndrome a risk factor for colorectal adenoma?. Cancer Epidemiol. Biomarkers Prev. 2007, 16:1543-1546.
24. Knupfer H., Preiss R. Serum interleukin-6 levels in colorectal cancer patients-a summary of published results. Int. J. Colorectal Dis. 2010, 25:135-140.
25. Koike Y., Miki C., Okugawa Y., Yokoe T., Toiyama Y., Tanaka K., Inoue Y., Kusunoki M. Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. J.Surg. Oncol. 2008, 98:540-544.
26. Lee J.H., Jeon S.M., Hong S.P., Cheon J.H., Kim T.I., Kim W.H. Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. Dig. Liver Dis. Official J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver 2012, 44:1042-1047.
27. Li L., Lee K.J., Choi B.C., Baek K.H. Relationship between leptin receptor and polycystic ovary syndrome. Gene 2013, 527:71-74.
28. Liu L., Zhong R., Wei S., Xiang H., Chen J., Xie D., Yin J., Zou L., Sun J., Chen W., Miao X., Nie S. The leptin gene family and colorectal cancer: interaction with smoking behavior and family history of cancer. PloS One 2013, 8:e60777.
29. Liu Z., Chang G.Q., Leibowitz S.F. Apolipoprotein D interacts with the long-form leptin receptor: a hypothalamic function in the control of energy homeostasis. FASEB J. Official Publ. Fed. Am. Societies Exp. Biol. 2001, 15:1329-1331.
30. Nagao K., Maeda M., Manucat N.B., Ueda K. Cyclosporine A and PSC833 inhibit ABCA1 function via direct binding. Biochim. Biophys. Acta 2013, 1831:398-406.
31. NCBI,. The National Center for Biotechnology Information. http://www.ncbi.nlm.nih.gov/.
32. Nikiteas N.I., Tzanakis N., Gazouli M., Rallis G., Daniilidis K., Theodoropoulos G., Kostakis A., Peros G. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J. Gastroenterol. 2005, 11:1639-1643.
33. Otvos L., Kovalszky I., Riolfi M., Ferla R., Olah J., Sztodola A., Nama K., Molino A., Piubello Q., Wade J.D., Surmacz E. Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur. J. Cancer 2011, 47:1578-1584.
34. Pais R., Silaghi H., Silaghi A.C., Rusu M.L., Dumitrascu D.L. Metabolic syndrome and risk of subsequent colorectal cancer. World J. Gastroenterol. 2009, 15:5141-5148.
35. Peters G., Gongoll S., Langner C., Mengel M., Piso P., Klempnauer J., Ruschoff J., Kreipe H., von Wasielewski R. IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Archiv. An Int. J. Pathol. 2003, 443:139-145.
36. Podzielinski I., Saunders B.A., Kimbler K.D., Branscum A.J., Fung E.T., DePriest P.D., van Nagell J.R., Ueland F.R., Baron A.T. Apolipoprotein concentrations are elevated in malignant ovarian cyst fluids suggesting that lipoprotein metabolism is dysregulated in epithelial ovarian cancer. Cancer Invest. 2013, 31:258-272.
37. Quasar Collaborative Group, Gray R., Barnwell J., McConkey C., Hills R.K., Williams N.S., Kerr D.J. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007, 370:2020-2029.
38. Rene Gonzalez R., Watters A., Xu Y., Singh U.P., Mann D.R., Rueda B.R., Penichet M.L. Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res. BCR 2009, 11:R36.
39. Sadanandam A., Wang X., de Sousa E.M.F., Gray J.W., Vermeulen L., Hanahan D., Medema J.P. Reconciliation of classification systems defining molecular subtypes of colorectal cancer: interrelationships and clinical implications. Cell Cycle 2014, 13:353-357.
40. Salazar R., Roepman P., Capella G., Moreno V., Simon I., Dreezen C., Lopez-Doriga A., Santos C., Marijnen C., Westerga J., Bruin S., Kerr D., Kuppen P., van de Velde C., Morreau H., Van Velthuysen L., Glas A.M., Van't Veer L.J., Tollenaar R. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.Clinical Oncol. Offic. J. Am. Soc. Clin. Oncol. 2011, 29:17-24.
41. Sharma R., Zucknick M., London R., Kacevska M., Liddle C., Clarke S.J. Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin. Colorectal Cancer 2008, 7:331-337.
42. Sinicrope F.A., Foster N.R., Sargent D.J., O'Connell M.J., Rankin C. Obesity is an independent prognostic variable in colon cancer survivors. Clin. Cancer Res. Official J. Am. Assoc. Cancer Res. 2010, 16:1884-1893.
43. Sinicrope F.A., Foster N.R., Yothers G., Benson A., Seitz J.F., Labianca R., Goldberg R.M., Degramont A., O'Connell M.J., Sargent D.J., Adjuvant Colon Cancer Endpoints, G Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer 2013, 119:1528-1536.
44. Slattery M.L., Wolff R.K., Herrick J., Caan B.J., Potter J.D. Leptin and leptin receptor genotypes and colon cancer: gene-gene and gene-lifestyle interactions. Int. J. Cancer J. Int. du Cancer 2008, 122:1611-1617.
45. Soiland H., Janssen E.A., Korner H., Varhaug J.E., Skaland I., Gudlaugsson E., Baak J.P., Soreide J.A. Apolipoprotein D predicts adverse outcome in women >or= 70 years with operable breast cancer. Breast Cancer Res. Treat. 2009, 113:519-528.
46. Soiland H., Soreide K., Janssen E.A., Korner H., Baak J.P., Soreide J.A. Emerging concepts of apolipoprotein D with possible implications for breast cancer. Cell Oncol. The Official J. Int. Soc. Cell Oncol. 2007, 29:195-209.
47. Spillane S., Bennett K., Sharp L., Barron T.I. A cohort study of metformin exposure and survival in patients with stage I-III colorectal cancer. Cancer Epidemiol. Biomarkers Prev. Public. Am. Assoc. Cancer Res. Cosponsored by Am. Soc. Prev. Oncol. 2013, 22:1364-1373.
48. Sveen A., Agesen T.H., Nesbakken A., Meling G.I., Rognum T.O., Liestol K., Skotheim R.I., Lothe R.A. ColoGuidePro: a prognostic 7-gene expression signature for stage III colorectal cancer patients. Clin. Cancer Res. Official J. Am. Assoc. Cancer Res. 2012, 18:6001-6010.
49. Takano S., Yoshitomi H., Togawa A., Sogawa K., Shida T., Kimura F., Shimizu H., Tomonaga T., Nomura F., Miyazaki M. Apolipoprotein C-1 maintains cell survival by preventing from apoptosis in pancreatic cancer cells. Oncogene 2008, 27:2810-2822.
50. Uddin S., Bavi P.P., Hussain A.R., Alsbeih G., Al-Sanea N., Abduljabbar A., Ashari L.H., Alhomoud S., Al-Dayel F., Ahmed M., Al-Kuraya K.S. Leptin receptor expression in Middle Eastern colorectal cancer and its potential clinical implication. Carcinogenesis 2009, 30:1832-1840.
51. van der Ham R.L., Alizadeh Dehnavi R., Berbee J.F., Putter H., de Roos A., Romijn J.A., Rensen P.C., Tamsma J.T. Plasma apolipoprotein CI and CIII levels are associated with increased plasma triglyceride levels and decreased fat mass in men with the metabolic syndrome. Diabetes Care 2009, 32:184-186.
52. Vermaat J.S., van der Tweel I., Mehra N., Sleijfer S., Haanen J.B., Roodhart J.M., Engwegen J.Y., Korse C.M., Langenberg M.H., Kruit W., Groenewegen G., Giles R.H., Schellens J.H., Beijnen J.H., Voest E.E. Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. Ann. Oncol. Offic. J. Eur. Soc. Med. Oncol.ESMO 2010, 21:1472-1481.
53. Wang L.Q., Shen W., Xu L., Chen M.B., Gong T., Lu P.H., Tao G.Q. The association between polymorphisms in the leptin receptor gene and risk of breast cancer: a systematic review and pooled analysis. Breast Cancer Res. Treat. 2012, 136:231-239.
54. Werneck M.B., Hottz E., Bozza P.T., Viola J.P. Cyclosporin A inhibits colon cancer cell growth independently of the calcineurin pathway. Cell Cycle 2012, 11:3997-4008.
55. Yang C.Y., Gu Z.W., Blanco-Vaca F., Gaskell S.J., Yang M., Massey J.B., Gotto A.M., Pownall H.J. Structure of human apolipoprotein D: locations of the intermolecular and intramolecular disulfide links. Biochemistry 1994, 33:12451-12455.
56. Yang Y., Mauldin P.D., Ebeling M., Hulsey T.C., Liu B., Thomas M.B., Camp E.R., Esnaola N.F. Effect of metabolic syndrome and its components on recurrence and survival in colon cancer patients. Cancer 2013, 119:1512-1520.